Next time you feel an itch, remember that your brain's vast network of neurons informs it whether it is an itch or pain. A ...

The chronic pruritus therapeutics market has seen a robust growth in recent years. It is forecasted to grow from $10.17 billion in 2024 to $10.94 billion in 2025, demonstrating a compound annual ...

The Chronic Pruritus Market is making significant strides, fueled by innovative treatment approaches and ongoing research advancements. DelveInsight’s latest 7MM report delivers deep insights ...

Given the late-breaking data on topical ruxolitinib's effectiveness in prurigo nodularis and its rapid itch relief, how do you foresee this impacting treatment paradigms for chronic pruritic ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on second-generation H1-antihistamines, it was found that remibrutinib more ...

Equities researchers at StockNews.com assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA – Get Free Report) in a ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Frequent scratching, licking or biting may be a sign that your wet-nosed companion needs veterinary care. Chronic itching and ...